Ruyi Xu
Impact in
- Immunology top 10%
- Immune cells in cancer
- Phagocytosis and Immune Regulation
-
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Multiple Myeloma Research and Treatments 4
- Co-authors
- Zhen CaiEnfan ZhangJianwei QuJingsong HeHaimeng YanHuiyao GuWen CaoYang Liu
- Journals
- International Journal of Legal Medicine (3 papers)Blood (3 papers)Infection and Drug Resistance (2 papers)Journal of Virology (2 papers)Biomarker Research (1 paper)
- Partner nations
- ChinaAustraliaUnited States
In The Last Decade
Ruyi Xu
27 papers receiving 639 citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Immunology 236
- Cancer Research 137
- Molecular Biology 330
- Oncology 88
- Biological Psychiatry 8
Countries citing papers authored by Ruyi Xu
This map shows the geographic impact of Ruyi Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruyi Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruyi Xu more than expected).
Fields of papers citing papers by Ruyi Xu
This network shows the impact of papers produced by Ruyi Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruyi Xu. The network helps show where Ruyi Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside Ruyi Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 1 | |
| 5 | 2023 | 4 | |
| 6 | 2023 | 2 | |
| 7 | Warming Menstruation and Analgesic Soup Inhibits PD-1/PD-L1 Pathway in Rats with Endometriosis. | 2023 | 2 |
| 8 | 2023 | 3 | |
| 9 | 2022 | 9 | |
| 10 | 2022 | 6 | |
| 11 | 2022 | 8 | |
| 12 | Metabolic reprogramming in macrophage responses Hit paper breakdown → | 2021 | 386 |
| 13 | 2021 | 38 | |
| 14 | 2020 | 35 | |
| 15 | 2020 | 19 | |
| 16 | 2020 | 10 | |
| 17 | 2019 | 42 | |
| 18 | 2019 | 1 | |
| 19 | 2019 | 0 | |
| 20 | 2010 | 6 |
About Ruyi Xu
Ruyi Xu is a scholar working on Family Practice, Hematology, Immunology, Oncology and Critical Care and Intensive Care Medicine, having authored 31 papers that have together received 644 indexed citations. Recurring topics across this work include RNA modifications and cancer (5 papers), Immune cells in cancer (5 papers), Multiple Myeloma Research and Treatments (4 papers), Forensic and Genetic Research (4 papers), Molecular Biology Techniques and Applications (4 papers), Cancer-related gene regulation (3 papers), Chemokine receptors and signaling (3 papers) and Sepsis Diagnosis and Treatment (3 papers). The work is most often cited by research in Immunology (236 citations), Cancer Research (137 citations), Molecular Biology (330 citations), Oncology (88 citations) and Biological Psychiatry (8 citations). Ruyi Xu has collaborated with scholars based in China, Australia and United States. Frequent co-authors include Zhen Cai, Enfan Zhang, Jianwei Qu, Jingsong He, Haimeng Yan, Huiyao Gu, Wen Cao, Yang Liu, Xi Huang and Tao Pan. Their work appears in journals such as International Journal of Legal Medicine, Blood, Infection and Drug Resistance, Journal of Virology and Biomarker Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.